Adoptive chimeric antigen receptor T cell (CAR-T) and Treg cell-based immunotherapies: Frontier therapeutic aspects in cancers

Based on this point that some of the cancers do not appropriately respond to conventional therapy and there is the possibility of relapse, immunotherapy is currently under investigation. Cancer immunotherapies are widely recognized as transformational for several cancers and enable to move to the fr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mehran Bahraini, Alieh Fazeli
Formato:	article
Lenguaje:	EN
Publicado:	Tehran University of Medical Sciences 2021
Materias:	tumor microenvironment chimeric t cell receptors regulatory t-lymphocytes adoptive immunotherapy Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/6dcd93027cb0443fad7ae673b4e7770f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6dcd93027cb0443fad7ae673b4e7770f
record_format	dspace
spelling	oai:doaj.org-article:6dcd93027cb0443fad7ae673b4e7770f2021-11-29T06:16:08ZAdoptive chimeric antigen receptor T cell (CAR-T) and Treg cell-based immunotherapies: Frontier therapeutic aspects in cancers0044-60251735-969410.18502/acta.v59i10.7760https://doaj.org/article/6dcd93027cb0443fad7ae673b4e7770f2021-11-01T00:00:00Zhttps://acta.tums.ac.ir/index.php/acta/article/view/8731https://doaj.org/toc/0044-6025https://doaj.org/toc/1735-9694Based on this point that some of the cancers do not appropriately respond to conventional therapy and there is the possibility of relapse, immunotherapy is currently under investigation. Cancer immunotherapies are widely recognized as transformational for several cancers and enable to move to the front-line therapy with few side effects. One of its new branches is treatment with T-cells that have been changed their receptor. The research on these cells is generally according to the design of a receptor against a specific tumor antigen. Also, manipulation of regulatory T-cell (Tregs), as the barriers to useful immune responses in the tumor microenvironment, will promote Tregs -targeted therapeutic opportunities and improve the efficacy of the current cancer treatment, such as radiation and chemotherapy. This review attempts to show novel insights into the roles of Tregs in cancer which can be considered as a promising anticancer therapeutic strategy for targeting them and approaches for generation of tumor antigen-specific T lymphocytes (AST) using chimeric antigen receptors.Mehran BahrainiAlieh FazeliTehran University of Medical Sciencesarticletumor microenvironmentchimeric t cell receptorsregulatory t-lymphocytesadoptive immunotherapyMedicine (General)R5-920ENActa Medica Iranica, Pp 570-577 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	tumor microenvironment chimeric t cell receptors regulatory t-lymphocytes adoptive immunotherapy Medicine (General) R5-920
spellingShingle	tumor microenvironment chimeric t cell receptors regulatory t-lymphocytes adoptive immunotherapy Medicine (General) R5-920 Mehran Bahraini Alieh Fazeli Adoptive chimeric antigen receptor T cell (CAR-T) and Treg cell-based immunotherapies: Frontier therapeutic aspects in cancers
description	Based on this point that some of the cancers do not appropriately respond to conventional therapy and there is the possibility of relapse, immunotherapy is currently under investigation. Cancer immunotherapies are widely recognized as transformational for several cancers and enable to move to the front-line therapy with few side effects. One of its new branches is treatment with T-cells that have been changed their receptor. The research on these cells is generally according to the design of a receptor against a specific tumor antigen. Also, manipulation of regulatory T-cell (Tregs), as the barriers to useful immune responses in the tumor microenvironment, will promote Tregs -targeted therapeutic opportunities and improve the efficacy of the current cancer treatment, such as radiation and chemotherapy. This review attempts to show novel insights into the roles of Tregs in cancer which can be considered as a promising anticancer therapeutic strategy for targeting them and approaches for generation of tumor antigen-specific T lymphocytes (AST) using chimeric antigen receptors.
format	article
author	Mehran Bahraini Alieh Fazeli
author_facet	Mehran Bahraini Alieh Fazeli
author_sort	Mehran Bahraini
title	Adoptive chimeric antigen receptor T cell (CAR-T) and Treg cell-based immunotherapies: Frontier therapeutic aspects in cancers
title_short	Adoptive chimeric antigen receptor T cell (CAR-T) and Treg cell-based immunotherapies: Frontier therapeutic aspects in cancers
title_full	Adoptive chimeric antigen receptor T cell (CAR-T) and Treg cell-based immunotherapies: Frontier therapeutic aspects in cancers
title_fullStr	Adoptive chimeric antigen receptor T cell (CAR-T) and Treg cell-based immunotherapies: Frontier therapeutic aspects in cancers
title_full_unstemmed	Adoptive chimeric antigen receptor T cell (CAR-T) and Treg cell-based immunotherapies: Frontier therapeutic aspects in cancers
title_sort	adoptive chimeric antigen receptor t cell (car-t) and treg cell-based immunotherapies: frontier therapeutic aspects in cancers
publisher	Tehran University of Medical Sciences
publishDate	2021
url	https://doaj.org/article/6dcd93027cb0443fad7ae673b4e7770f
work_keys_str_mv	AT mehranbahraini adoptivechimericantigenreceptortcellcartandtregcellbasedimmunotherapiesfrontiertherapeuticaspectsincancers AT aliehfazeli adoptivechimericantigenreceptortcellcartandtregcellbasedimmunotherapiesfrontiertherapeuticaspectsincancers
_version_	1718407590755434496

Adoptive chimeric antigen receptor T cell (CAR-T) and Treg cell-based immunotherapies: Frontier therapeutic aspects in cancers

Ejemplares similares